FDA Approves JNJ & MRNA's COVID-19 Boosters & Mixing of Doses
The FDA authorizes booster doses of COVID-19 vaccines of JNJ and MRNA. It also authorizes a heterologous boosting option which will allow administration of booster dose of any available vaccine...
The FDA has granted emergency use authorization (“EUA”) to booster doses of Johnson & Johnson’s JNJ single-shot COVID-19 vaccine and Moderna’s MRNA mRNA-based COVID-19 vaccine, mRNA-1273. The United States now has authorized booster doses of three COVID-19 vaccines. The third vaccine is Pfizer PFE and BioNTech’s BNTX mRNA-based vaccine, Comirnaty, whose booster dose was authorized by the FDA last month.
In an unexpected turn of events, the FDA also authorized the mix and match or heterologous administration of the booster doses of the three COVID-19 vaccines. The heterologous administration will allow inoculation of an individual with any of the three available booster jabs irrespective of the initial COVID-19 vaccine regimen.
Booster Dose Eligibility
J&J’s booster dose is now authorized for use in all adults who have completed at least two months of their primary vaccination with J&J’s single-shot COVID-19 vaccine. Moderna received authorization for emergency use of the booster dose of mRNA-1273 after at least six months of the initial two-dose regimen in people aged 65 years or older (elderly), and in adults aged 18 or older who at high risk of severe COVID-19 or whose exposure to COVID-19 puts them at a risk of complications or severe illness. Comirnaty’s booster dose is also authorized for a similar population and dosing interval as Moderna’s vaccine.
The mix-and-match administration will allow administration of J&J’s booster jab in elderly and high-risk adults who have received mRNA-1273 or Comirnaty during the initial regimen and after at least six months of primary vaccination. In a similar manner, the booster dose of mRNA-1273 or Comirnaty can be administered to all adults who have received J&J’s single-shot vaccine initially following a dosing interval of two months.
Shares of all the aforementioned COVID-19 vaccine makers were up in after-hours trading on Oct 20, following the unexpected heterologous administration authorizations.
Why Mix and Match?
The FDA authorized the mix and match administration based on clinical data from study conducted by the National Institute of Allergy and Infectious Diseases (NIAID). The data demonstrated that the benefits of the use of a single heterologous booster dose outweigh risks.
Several health experts have been voicing support for the mix and match administration of booster doses for a better vaccination program. There have been cases of allergic reactions in individuals receiving a certain COVID-19 vaccine. Some regions in the United States do not have all the three booster vaccines available simultaneously. The heterologous administration will alleviate these shortcomings. A person who has had a side-effect after receiving a mRNA-based vaccine can be administered J&J’s adeno-virus based booster vaccine and vice-versa. Moreover, the availability of any of the authorized booster doses in a region will allow the booster vaccination program to continue.
Also, the FDA’s authorization of heterologous administration will ease the concerns related to use of a different booster jab than the initial regimen.
While Pfizer carries a Zacks Rank #2 (Buy), Moderna, J&J and BioNTech carry a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Infrastructure Stock Boom to Sweep America
A massive push to rebuild the crumbling U.S. infrastructure will soon be underway. It’s bipartisan, urgent, and inevitable. Trillions will be spent. Fortunes will be made.
The only question is “Will you get into the right stocks early when their growth potential is greatest?”
Zacks has released a Special Report to help you do just that, and today it’s free. Discover 7 special companies that look to gain the most from construction and repair to roads, bridges, and buildings, plus cargo hauling and energy transformation on an almost unimaginable scale.Download FREE: How to Profit from Trillions on Spending for Infrastructure >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Johnson & Johnson (JNJ): Free Stock Analysis Report
Pfizer Inc. (PFE): Free Stock Analysis Report
Moderna, Inc. (MRNA): Free Stock Analysis Report
BioNTech SE Sponsored ADR (BNTX): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research